VC-Backed Trillium to merge with Stem Cell Therapeutics
Toronto-based Trillium Therapeutics Inc., which specializes in immunotherapy and cancer stem cell research, is merging with Stem Cell Therapeutics Corp., also a Toronto-based life sciences company. Under the terms of the deal, which will be closed in the first quarter of 2013, Trillium's security holders will receive C$1.2 million in cash and C$1.65 million in common shares in the new enterprise. Trillium has been backed by a number of Canadian venture capital firms since 1997.
5 February 2013•8 mins read
